02. Drug development: something old, something new  
Friday, 04 December 2015, 12:30-13:30

Chair: To be confirmed

Track: Drug-sensitive TB care and treatment, including trials

PC-708-04 Laboratory and non-clinical evaluation of pulmonary drug delivery in TB  
S Pandya, A Gupta, R Ranjan, M Sachan, A Srivastava, A Misra (India)

PC-709-04 Can vitamin C augment sputum conversion in TB patients while on anti-tuberculosis treatment?  
L Gujral, S Mugudalabetta, R K Ramalingapuram Muthuslohay (India)

PC-710-04 Identification of optimal dose and dosing regimen of clofazimine for the treatment of MDR-TB based on pharmacokinentic modeling  
G Subramanian, G Sunkara, D Mcneeley, D Hughes (India, USA, Switzerland)

PC-711-04 A comparison of the effectiveness of a six- versus eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions  
K Ukwaja, S Oshi, I Alobu, D Oshi (Nigeria)

PC-712-04 Therapeutic drug monitoring of isoniazid and rifampicin  
L Moreno Exebio, L Lecca, G R Davies (Peru, UK)

PC-713-04 Plasma concentration of first-line anti-tuberculosis drugs in relation to minimal inhibitory concentrations: a prospective observational study  
K Niward, L Davies-Forsman, J Bruchfeld, J Paues, E Eliasson, J Werngren, U Simonsson, T Schön (Sweden)

PC-714-04 The role of wild-type distributions and epidemiological cut-offs in determining breakpoints for susceptibility testing against M. tuberculosis  
T Schön (Sweden)

PC-715-04 Spectinamides: a new class of semisynthetic protein synthesis inhibitors against tuberculosis that overcome native drug efflux  

PC-716-04 Comparing the efficacy of drug regimens for patients with drug-sensitive pulmonary tuberculosis – an aggregate data meta-analysis of phase II studies  
L Bonnett, G R Davies (UK)